Resolution of issues from the company’s past and its historical legal challenges has remained a critical priority to secure certainty for our future. While we appreciate the court and jury’s time, attention, and professionalism throughout the trial, we are pleased to have reached a settlement with the state and will work to finalize this agreement over the coming weeks. We have now settled with 48 states and territories, providing over $1 billion to participating states to further combat underage use and develop cessation programs. This is in addition to our global resolution of the U.S. private litigation that covers more than 5,000 cases brought by approximately 10,000 plaintiffs.
As we reach total resolution of the company’s past, we are focused on our path forward to maximize the value and impact of our product technology and scientific foundation. Our technology already has transitioned over two million adult smokers from combustible cigarettes. And our priorities remain to secure authorization of our PMTAs based on the science and lead the category with innovation to accelerate our mission and advance tobacco harm reduction for over 31 million adult smokers in the U.S. and over 1 billion adult smokers worldwide.
October 2, 2024
On September 26th, Juul Labs’ Chairman & Chief Executive Officer, K.C. Crosthwaite, delivered the keynote address at the 2024 Global Tobacco & Nicotine Forum,…
July 29, 2024
Juul Labs announced today the settlement with a group of noteholders that confirms the conversion of the convertible notes to equity, and provides an…
June 6, 2024
Today, the FDA rescinded its June 2022 Marketing Denial Orders (MDOs) for the JUUL System and placed our applications back into scientific review. We appreciate the FDA’s decision and now look forward to re-engaging with the agency on a science- and evidence-based process to pursue a marketing authorization for JUUL products.